Bone scan imaging to help plan radiotherapy for prostate cancer spread to bone
Tests a whole-body bone scan to plan radiotherapy in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy
Key facts
- Where
- Rouen, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread to the bones and who are due to have bone stereotactic radiotherapy. It tests a whole-body bone SPECT/CT scan for planning that treatment.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate cancer with bone metastases, with an indication for bone stereotactic radiotherapy. Good general health (WHO ≤ 1).
- Earlier treatment
- No earlier radiotherapy of the area that would be treated with stereotactic radiotherapy.
Main reasons for not taking part
- Active cancer in the previous three years
- Adults under guardianship or curatorship
- Unable to lie down flat for the scan (for example orthopnea)
- Hypersensitivity to HDP or to an ingredient of the radiopharmaceutical
- Earlier radiotherapy of the area to be treated
Read by machine on 12 November 2026.
Where in France
- Centre Henri BecquerelRouen, FranceContact: Arnaud Dieudonne, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Henri Becquerel
- Trial code
- NCT06439784
- Record updated
- 24 July 2026
- Original description
Stereotactic radiotherapy enables bone metastases to be treated with highly precise irradiation beams, enabling small targets to be irradiated. Planning requires the use of cross-sectional imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). Bone scintigraphy with Tc99m-labelled biphosphonates (T1/2=6h) is indicated in the extension assessment of prostate cancers. Thanks to the advent of single-photon emission computed tomography (SPECT) based on CZT detectors; whole-body SPECT is now compatible with clinical constraints. We propose to study the value of using whole-body SPECT for planning stereotactic radiotherapy of metastatic prostate cancer. This is a prospective, single-center, non-randomized study involving 30 patients. Patients will benefit from routine examinations (CT scan, MRI) including a bone SPECT/CT in treatment position performed on the VERITON-CT (Spectrum Dynamics, Haifa, Israel). Planning based on whole-body SPECT images will be carried out remotely from the patient's point of care. The examination will be interpreted by the nuclear physician, and planning will be based on the dosimetric CT scanner, as in standard management. Virtual replanning will be carried out at distance from treatment, incorporating SPECT imaging. Treatment plans with and without SPECT will be compared quantitatively and qualitatively. The feasibility of SPECT imaging in the treatment position will be assessed, enabling lesion location imaging and dosimetric scanning to be performed in a single examination. All therapeutic management and clinical follow-up will be carried out as part of routine care.Read full original descriptionShow less
Contribution of 99mTc-HDP Whole-body SPECT/CT Imaging by VERITON-CT CZT Camera in Stereotactic Radiotherapy Treatment of Bone Metastases of Prostate Cancer
Stereotactic radiotherapy enables bone metastases to be treated with highly precise irradiation beams, enabling small targets to be irradiated. Planning requires the use of cross-sectional imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). Bone scintigraphy with Tc99m-labelled biphosphonates (T1/2=6h) is indicated in the extension assessment of prostate cancers. Thanks to the advent of single-photon emission computed tomography (SPECT) based on CZT detectors; whole-body SPECT is now compatible with clinical constraints. We propose to study the value of using whole-body SPECT for planning stereotactic radiotherapy of metastatic prostate cancer. This is a prospective, single-center, non-randomized study involving 30 patients. Patients will benefit from routine examinations (CT scan, MRI) including a bone SPECT/CT in treatment position performed on the VERITON-CT (Spectrum Dynamics, Haifa, Israel). Planning based on whole-body SPECT images will be carried out remotely from the patient's point of care. The examination will be interpreted by the nuclear physician, and planning will be based on the dosimetric CT scanner, as in standard management. Virtual replanning will be carried out at distance from treatment, incorporating SPECT imaging. Treatment plans with and without SPECT will be compared quantitatively and qualitatively. The feasibility of SPECT imaging in the treatment position will be assessed, enabling lesion location imaging and dosimetric scanning to be performed in a single examination. All therapeutic management and clinical follow-up will be carried out as part of routine care.
Inclusion: Age ≥ 18 years,; Good general health WHO ≤ 1; Informed and signed consent prior to any specific study procedure; Patient affiliated to the social security system; Bone metastases from prostate cancer; Indication for bone stereotactic radiotherapy.
Exclusion: Presence of active cancer in the previous three years; Hypersensitivity to HDP or to one of the excipients of the radiopharmaceutical; History of radiotherapy of the volume to be treated by stereotaxy; Protected adults (under guardianship or curatorship); Unable to undergo medical monitoring for geographical, social or psychological reasons; Unable to decubitus (orthopnea, etc.),.